Analyst Comment EyePoint advances with Duravyu Phase III trial KOLs interviewed by GlobalData have praised Duravyu’s initial clinical data. GlobalData Healthcare
Analyst Comment ATS 2025: ETI-linked mucus clearance tied to lung function gains in paediatric CF GlobalData Healthcare
Analyst Comment ATS 2025: Anti–IL-5 therapy cuts exacerbations in coexisting COPD and asthma patients GlobalData Healthcare
Analyst Comment ATS 2025: Real-world data supports Trikafta as gold standard in long-term CF care GlobalData Healthcare
Analyst Comment ATS 2025: Tezepelumab reduces COPD exacerbations in eosinophilic patients, despite CB GlobalData Healthcare
Analyst Comment ATS 2025: Nucala reduces COPD exacerbations, regardless of severe event history GlobalData Healthcare
Analyst Comment Five years, one approval: Europe’s slow march on Alzheimer’s treatments GlobalData Healthcare
Analyst Comment Revamping US pharma manufacturing: Trump’s executive order faces industry doubts GlobalData Healthcare
Analyst Comment 5EU Q1 2024 versus 2025: Pricing shifts, HTA outcomes, and innovative drug trends Simran Gurung
Analyst Comment Pharma M&A deal value surges by 101% QoQ in Q1 2025 despite US political turbulence GlobalData Healthcare
Analyst Comment GLP-1 receptor agonists poised to redefine treatment paradigms beyond diabetes and obesity GlobalData Healthcare
Analyst Comment Biopharma venture financing declines 20.2% YOY in Q1 2025 amid persistent investor caution GlobalData Healthcare
Analyst Comment Impending US tariffs signal uncertain future for global pharma, says GlobalData GlobalData Healthcare
Analyst Comment US tariffs likely to disrupt drug development costs and prices, says GlobalData GlobalData Healthcare
Analyst Comment Top 20 biopharmas’ market cap rises 6% in Q1 2025 amid tariff headwinds GlobalData Healthcare
Analyst Comment First two medicinal products to undergo EU joint clinical assessments announced Brendan Melck
Analyst Comment The 7MM atopic dermatitis market to experience growth, reaching $22.4bn by 2033 GlobalData Healthcare
Analyst Comment Do in vivo CAR-T cell therapies have the potential to overtake ex vivo CAR-Ts? GlobalData Healthcare
Analyst Comment ESCMID Global 2025: Climate-informed infectious disease risk management GlobalData Healthcare
Analyst Comment AAN 2025: Long-term outcome data on steroid regimens in MG may guide treatment standards GlobalData Healthcare
Analyst Comment AD/PD 2025: Reporting of first real-world data for Leqembi focuses on operational challenges and safety GlobalData Healthcare
Analyst Comment AD/PD 2025: First real-world data report for Leqembi focuses on operational challenges GlobalData Healthcare
Analyst Comment IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility GlobalData Healthcare
Analyst Comment AD/PD 2025: DHTs can detect disease progression in patients with early Parkinson’s GlobalData Healthcare
Analyst Comment IO360 summit: CAR-T cell therapy applications beyond blood cancer GlobalData Healthcare
Analyst Comment Weight loss implants to increase compliance and cut admin burden for patients GlobalData Healthcare